The use of anti-interleukin-12/23 agents and major adverse cardiovascular events

Archives of Dermatology

Volumn 148, Issue 6, 2012, Pages 753-754

  Bigby, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; PLACEBO; USTEKINUMAB;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; DEATH; DRUG SAFETY; DRUG USE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84862690768     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2618     Document Type: Note

References (5)

1. Bigby M, Corona R, Szklo M. Evidence-based medicine. In: Freedberg IM, Eisen AZ, Wolf K, Austen, KF, Goldsmith LA, Katz SI. Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2008.
2. Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet. 2009; 373(9679):1926-1928. doi:10.1016/S0140-6736(09)60499-2.
3. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317 (7168):1309-1312. (Pubitemid 28502420)
4. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733.
5. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol. 2009;146(1):27-30.